- Home
- EDN vs PHVS Comparison
EDN vs PHVS Comparison
Compare EDN & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDN | PHVS |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | Argentina | Switzerland |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EDN | PHVS |
|---|---|---|
| Price | $31.45 | $25.82 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $39.44 |
| AVG Volume (30 Days) | 114.0K | ★ 532.0K |
| Earning Date | 08-11-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $1,678,118,877.00 | N/A |
| Revenue This Year | $32.93 | N/A |
| Revenue Next Year | $24.64 | N/A |
| P/E Ratio | $20.19 | ★ N/A |
| Revenue Growth | ★ 3.69 | N/A |
| 52 Week Low | $14.38 | $11.51 |
| 52 Week High | $48.44 | $29.80 |
Technical Indicators
Market Signals| Indicator | EDN | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 51.77 | 54.34 |
| Support Level | $29.01 | $23.79 |
| Resistance Level | $33.08 | $25.44 |
| Average True Range (ATR) | 2.17 | 1.91 |
| MACD | -0.47 | -0.17 |
| Stochastic Oscillator | 32.77 | 41.22 |
Price Performance
Historical ComparisonAbout EDN Empresa Distribuidora Y Comercializadora Norte S.A. (Edenor)
Empresa Distribuidora y Comercializadora Norte SA is engaged in the distribution and sale of electricity. The firm's concession area covers the northern portion of the city of Buenos Aires mainly to residential, commercial, industrial, and public service.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.